KEY PUBLICATIONS

  1. Ne E, Crespo R, Izquierdo-Lara R, Rao S, Koçer S, Górska A, van Staveren T, Kan TW, van de Vijver D, Dekkers D, Rokx C, Moulos P, Hatzis P, Palstra RJ, Demmers J, Mahmoudi T. Catchet-MS identifies IKZF1-targeting thalidomide analogues as novel HIV-1 latency reversal agents. Nucleic Acids Res. 2022 Jun 10;50(10):5577-5598. 

  2. Crespo R, Rao S, Mahmoudi T. HibeRNAtion: HIV-1 RNA Metabolism and Viral Latency. Front Cell Inf Micro. 2022. Jun 14 https://doi.org/10.3389/fcimb.2022.855092

  3. Rao S, Mahmoudi T. DEAD-ly Affairs: The Roles of DEAD-Box Proteins on HIV-1 Viral RNA Metabolism Front Cell Inf Micro. 2022. Jun 13 https://doi.org/10.3389/fcell.2022.917599

  4. Hossain T, Romal S, Mahmoudi T. Production of Recombinant Hepatitis B virus (HBV) and Detection of HBV in Infected Human Liver Organoids. Bio Protoc. 2022;12(8):e4392. Published 2022 Apr 20. doi:10.21769/BioProtoc.4392

  5. Romal S, Hossain T, Mahmoudi T. Generation, Maintenance and HBV Infection of Human Liver Organoids. Bio Protoc. 2022;12(6):e4358. Published 2022 Mar 20. doi:10.21769/BioProtoc.4358

  6. Rao S, Lungu C, Crespo R, Steijaert TH, Gorska A, Palstra RJ, et al. Selective cell death in HIV-1-infected cells by DDX3 inhibitors leads to depletion of the inducible reservoir. Nat Commun. 2021;12(1):2475.

  7. De Crignis E, Hossain T, Romal S, Carofiglio F, Moulos P, Khalid MM, et al. Application of human liver organoids as a patient-derived primary model for HBV infection and related hepatocellular carcinoma. Elife. 2021;10

  8. Stoszko M, Al-Hatmi AMS, Skriba A, Roling M, Ne E, Crespo R, et al. Gliotoxin, identified from a screen of fungal metabolites, disrupts 7SK snRNP, releases P-TEFb, and reverses HIV-1 latency. Sci Adv. 2020;6(33):eaba6617.

  9. Lungu C, Procopio FA, Overmars RJ, Beerkens RJJ, Voermans JJC, Rao S, et al. Inter-Laboratory Reproducibility of Inducible HIV-1 Reservoir Quantification by TILDA. Viruses. 2020;12(9).

  10. Crespo R, Rokx C, Mahmoudi T. Towards the next step: LoViRet patients for HIV-1 cure studies. EBioMedicine. 2020;58:102889.

  11. Bertoldi A, D'Urbano V, Bon I, Verbon A, Rokx C, Boucher C, et al. Development of C-TILDA: A modified TILDA method for reservoir quantification in long term treated patients infected with subtype C HIV-1. J Virol Methods. 2020;276:113778.

  12. Zhao M, De Crignis E, Rokx C, Verbon A, van Gelder T, Mahmoudi T, et al. T cell toxicity of HIV latency reversing agents. Pharmacol Res. 2019;139:524-34.

  13. Stoszko M, Ne E, Abner E, Mahmoudi T. A broad drug arsenal to attack a strenuous latent HIV reservoir. Curr Opin Virol. 2019;38:37-53.

  14. Palstra RJ, de Crignis E, Roling MD, van Staveren T, Kan TW, van Ijcken W, et al. Allele-specific long-distance regulation dictates IL-32 isoform switching and mediates susceptibility to HIV-1. Sci Adv. 2018;4(2):e1701729.

  15. Ne E, Palstra RJ, Mahmoudi T. Transcription: Insights From the HIV-1 Promoter. Int Rev Cell Mol Biol. 2018;335:191-243.

  16. Marian CA, Stoszko M, Wang L, Leighty MW, de Crignis E, Maschinot CA, et al. Small Molecule Targeting of Specific BAF (mSWI/SNF) Complexes for HIV Latency Reversal. Cell Chem Biol. 2018;25(12):1443-55 e14.

  17. Abner E, Stoszko M, Zeng L, Chen HC, Izquierdo-Bouldstridge A, Konuma T, et al. A New Quinoline BRD4 Inhibitor Targets a Distinct Latent HIV-1 Reservoir for Reactivation from Other "Shock" Drugs. J Virol. 2018;92(10).

  18. De Crignis E, Mahmoudi T. The Multifaceted Contributions of Chromatin to HIV-1 Integration, Transcription, and Latency. Int Rev Cell Mol Biol. 2017;328:197-252.

  19. Stoszko M, De Crignis E, Rokx C, Khalid MM, Lungu C, Palstra RJ, et al. Small Molecule Inhibitors of BAF; A Promising Family of Compounds in HIV-1 Latency Reversal. EBioMedicine. 2016;3:108-21.

  20. Rafati H, Parra M, Hakre S, Moshkin Y, Verdin E, Mahmoudi T. Correction: Repressive LTR Nucleosome Positioning by the BAF Complex Is Required for HIV Latency. PLoS Biol. 2015;13(11):e1002302.

  21. De Crignis E, Mahmoudi T. HIV eradication: combinatorial approaches to activate latent viruses. Viruses. 2014;6(11):4581-608.

  22. Mahmoudi T. The BAF complex and HIV latency. Transcription. 2012;3(4):171-6.

  23. Rafati H, Parra M, Hakre S, Moshkin Y, Verdin E, Mahmoudi T. Repressive LTR nucleosome positioning by the BAF complex is required for HIV latency. PLoS Biol. 2011;9(11):e1001206.